In a randomized, double‑blind 4‑month trial of middle‑aged overweight adults, oral urolithin A improved hamstring strength (~10–12%), increased peak VO2 and 6‑minute walk distance (clinically meaningful at 33 m for 1,000 mg), altered mitochondrial proteomic signatures, and reduced inflammation without major safety signals.